Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Review Article Volume 3 Issue 5

COVID-19 Treatment and Post-COVID-19 Complication Syndrome: A Review

SM Rathnasiri Bandara1*, S Samita2, SS Hettiarachchi3 and SMTN Senanayaka4

1Senier Medical Officer and an Inverter, Department of Outpatient Department, Teaching Hospital Peradeniya, Sri Lanka
2Senior Professor Department of Crop Science, Professor of Statistics, Faculty of Agriculture, University of Peradeniya, Sri Lanka
3M.Sc. in Nanoscience and Nanotechnology by Coursework, Former Teaching Assistants, Department of Chemistry, Faculty of Science, University of Peradeniya, Sri Lanka
4Medical Students, Faculty of Medicine, University of Ruhuna, Sri Lanka

*Corresponding Author: SM Rathnasiri Bandara, Senier Medical Officer and an Inverter, Department of Outpatient Department, Teaching Hospital Peradeniya, Sri Lanka.

Received: March 30, 2020; Published: April 24, 2020



  The novel coronavirus disease 2019 caused by the SARS-Cov-2 virus belonging to the coronaviridae family to which SARS-CoV and MERS-CoV belonged. Therefore, viral immunopathology and treatment plane of COVID-19 have been explained based mainly on SARS-CoV2 as well as the known similar viral immunopathology to SARS. The major pathogenic mechanisms of COVID-19 include excesses activation of cytokines and chemokines, deficiencies in the innate immune response, direct involvement of immune cells, direct viral cytopathic effects, down-regulation of lung-protective angiotensin-converting enzyme 2 (ACE2), autoimmunity and genetic factors. The key factors seem that both abnormal immune responses and injury to immune cells increase in the production of inflammatory cytokines, autoantibodies and complement proteins leading to tissue damage. For these possible and obvious immunes - mediated life-threatening complications of viral infection, antiviral drugs, interferon, hydroxyl chloroquine, and TMPRSS2 inhibitor have been used in standard protocol against the COVID-19 immunopathology. It seems to have a lack of efficacy of the drugs due to the inability to stop all vulnerable steps of the immune pathology of the disease. Therefore, there is still no recognized or recommended or standard immune regulative treatment plan for COVID 19. Thus, considerations of all these backgrounds, “5S 5T Approach to battle COVID-19 approach including new corticosteroids protocol for COVID-19 and has been introduced targeting to stop or suppress life-threatening immune pathology of SARS-2 infection. It is also included the other alternative methods practiced by general community and traditional approaches. Especially the steroids protocol has been planned in the review with deeply considering avoiding the experience of unsuccessful approaches that caused many harmful effects such as high motility, viremia, increased viral load, no effect, side effect, fungal illness, hyperglycemia, and secondary infections. This review has been considered and described immunological changes in each phase of viral illness and the effective steroid protocol to manage at the pre-preliminary phase, early phase, and middle phase, severe/critical phase and post-viral infected phase (post COVID19 complication syndrome). This new protocol that is open to change and alteration is proposed.

Keywords: COVID-19; SARS-2; Corticosteroids Protocol; Viral Immunopathology



  1. Wang C., et al. “A novel coronavirus outbreak of global health concern”. Lancet 395 (2020): 470-473.
  2. Xu X., et al. “Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission”. Science China Life Sciences (2020).
  3. World-Health-Organization Statement on the second meeting of the International Health Regulations (2005).
  4. Ewen Callaway., et al. “The coronavirus pandemic in five powerful charts”. Nature (2020).
  5. Mary Van Beusekom. “Deeply concerned' WHO declares COVID-19 pandemic” (2020).
  6. COVID-19 Coronavirus Pandemic (2020): 23.
  7. Chan JFW., et al. “Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan”. Emerging Microbes and Infections 9 (2020): 221-236.
  8. S M Rathnasiri Bandara., et al. “Management of Dengue and Post Dengue Complication Syndrome: A Review”. ACTA Scientific Microbiology4 (2020).
  9. SM Rathnasiri Bandaraa and HMMTB Herathb. “Effectiveness of corticosteroid in the treatment of dengue – A systemic review”. Heliyon9 (2018): e00816.
  10. SM Rathnasiri Bandara and HMMTB Herat. Corticosteroid actions on dengue immune pathology; A review article (2019).
  11. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). CDC. Coronavirus Disease 2019 (COVID-19) (2019).
  12. Lee N., et al. “Wong Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients”. Journal of Clinical Virology 4 (2004): 304-309.
  13. Sasmita Poudel Adhikari., et al. “Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review”. Infectious Diseases of Poverty 1 (2020): 29.
  14. Ying-Ying Zheng., et al. “COVID-19 and the cardiovascular system”. Nature Reviews Cardiology (2020).
  15. Sinha A and Bagga A. “Pulse steroid therapy”. Indian Journal of Pediatrics 10 (2008): 1057-1066.
  16. Steer SA and Corbett JA. “The role and regulation of COX-2 during viral infection”. Viral Immunology 4 (2003): 447-460.
  17. Lin C-K., et al. “Cyclooxygenase‐2 facilitates dengue virus replication and serves as a potential target for developing antiviral agents”. Scientific Reports 1 (2017): 299.
  18. Kenneth McIntosh., et al. “Coronavirus disease 2019 (COVID-19)” (2020).
  19. Jia Liu., et al. “Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection In vitro”. Cell Discovery (2020).
  20. Welliver R Monto., et al. “Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial”. Journal of the American Medical Association 285 (2001): 748-754.
  21. Holshue ML., et al. “First case of 2019 novel coronavirus in the United States”. The New England Journal of Medicine (2019).
  22. Recombinant Interferon alfa-2B, a leading Cuban biotechnology product... the epidemic (COVID-19) caused by Coronavirus (SARS-CoV-2) (2020).
  23. Markus Hoffmann., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor” Journal Cell (2020).
  24. Fu-Shi Quan., et al. “Universal and reusable virus deactivation system for respiratory protection”. Scientific Reports (2017).
  25. Coronavirus Age, Sex, Demographics (COVID-19)-Worldometer (2020).
  26. Frequently Asked Questions and Answers: Coronavirus Disease-2019 (COVID-19) and Children (2019).
  27. Moniruzzaman M., et al. “Melatonin ameliorates H2O2-induced oxidative stress through modulation of Erk/Akt/NFkB pathway”. Biological Research 51 (2018): 17.
  28. Xuesong Sang., et al. “Vitamin C inhibits the activation of the NLRP3 inflammasome by scavenging mitochondrial ROS”. Inflammasome 2 (2016): 13-19.
  29. Jose Martinez., et al. “Antiviral effects of green tea (Camellia sinensis) against pathogenic viruses in human and animals (a mini-review)”. Article in African Journal of Traditional, Complementary and Alternative Medicines (2016).
  30. KV Tushar., et al. “Coscinium fenestratum (Gaertn.) Colebr.-A Review”. Journal of Plant Sciences 3 (2008): 133-145.
  31. Fabian M Dayrit and Mary T Newport. “The Potential of Coconut Oil and its Derivatives as Effective and Safe Antiviral Agents Against the Novel Coronavirus (nCoV-2019)”.
  32. Dahai Luo and Julien Lescar “The flavivirus NS2B–NS3 protease–helicase as a target for antiviral drug development”. Journal of Antiviral (2015).
  33. Weber ND., et al. “In vitro virucidal effects of Allium sativum (garlic) extract and compounds”. Planta Medicine5 (1992): 417-423.
  34. Onyilofe Sunday Enejoh., et al. “Ethnomedical Importance of Citrus aurantifolia (Christm) Swingle”. The Pharma Innovation Journal8 (2015): 1-6.
  35. Benjamin D Tanner. “Contaminated surfaces with a novel, portable, saturated steam vapor disinfection system”. American Journal of Infection Control1 (2008): 20-27.
  36. Tomohisa Ichiba., et al. “Warm Steam Inhalation before Bedtime Improved Sleep Quality in Adult Men”. Evidence-Based Complementary and Alternative Medicine (2019):
  37. KH Chan., et al. “The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus”. Advances in Virology (2011): 734690.
  38. J Sun., et al. “Effects of curcumin or dexamethasone on lung ischaemia–reperfusion injury in rats”. European Respiratory Journal 33 (2009): 398-404.
  39. Julie Brown., et al. “Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth”. Cochrane Database of Systematic Reviews 3 (2017): CD004454.
  40. Sinha A and Bagga A. “Pulse steroid therapy”. Indian Journal of Pediatrics 10 (2008): 1057-1066.
  41. Matsuyama S., et al. “The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15”. bioRxiv (2020).
  42. Hui Li., et al. “Effect of low‐to‐moderate‐dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia”. Influenza Other Respir Viruses4 (2017): 345-354.
  43. Koichiro Kudo., et al. “Systemic Corticosteroids and Early Administration of Antiviral Agents for Pneumonia with Acute Wheezing due to influenza A(H1N1)pdm09 in Japan”. PLoS One2 (2012): e32280.
  44. Awen Menou., et al. “Type II Transmembrane Serine Proteases”. Journal of Biological Chemistry35 (2009): 23177-23181.
  45. Nasef Abdelsalam and RezkAmer Mohamed Ibrahim. “Effects of methyl prednisolone in early ARDS”. Egyptian Journal of Chest Diseases and Tuberculosis1 (2013).


Citation: SM Rathnasiri Bandara., et al. “COVID-19 Treatment and Post-COVID-19 Complication Syndrome: A Review". Acta Scientific Microbiology 3.5 (2020): 103-118.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US